Cargando…
Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
BACKGROUND: Ruxolitinib improves splenomegaly and symptoms in patients with intermediate-2 or high-risk myelofibrosis; however, nearly half develop grade 3/4 anemia and/or thrombocytopenia, necessitating dose reductions and/or transfusions. We report findings from an open-label phase 2 study explori...
Autores principales: | Talpaz, Moshe, Erickson-Viitanen, Susan, Hou, Kevin, Hamburg, Solomon, Baer, Maria R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081850/ https://www.ncbi.nlm.nih.gov/pubmed/30086777 http://dx.doi.org/10.1186/s13045-018-0642-0 |
Ejemplares similares
-
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
por: Talpaz, Moshe, et al.
Publicado: (2013) -
Sustained‐release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis
por: Verstovsek, Srdan, et al.
Publicado: (2018) -
Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence
por: Harrison, Claire N., et al.
Publicado: (2016) -
Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013) -
A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis
por: Harrison, Claire, et al.
Publicado: (2022)